Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in the ciliary neurotrophic factor of the spinal cord in amyotrophic lateral sclerosis.

S Ono1, T Imai, A Igarashi

  • 1Department of Neurology, Teikyo University School of Medicine, Ichihara Hospital, Ichihara, Japan.

European Neurology
|October 26, 1999
PubMed
Summary

Ciliary neurotrophic factor (CNTF) levels in the spinal cord tend to decrease in amyotrophic lateral sclerosis (ALS) patients. This reduction, particularly significant in homozygotes within the lateral corticospinal tract, may contribute to motor neuron loss in ALS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence, risk factors, and clinical implications of enfortumab vedotin-related cutaneous toxicity in urothelial carcinoma: a large-scale, real-world study in Japan.

ESMO real world data and digital oncology·2026
Same author

The impact of omalizumab on paid and unpaid work productivity among severe Japanese cedar pollinosis (JCP) patients.

Journal of medical economics·2022
Same author

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

The British journal of dermatology·2021
Same author

Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.

The British journal of dermatology·2019
Same author

Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.

The British journal of dermatology·2019
Same author

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study.

The British journal of dermatology·2019

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Ciliary neurotrophic factor (CNTF) is a known survival factor for spinal motoneurons.
  • CNTF is being explored as a potential treatment for amyotrophic lateral sclerosis (ALS).
  • The precise role of CNTF in the pathology of ALS is not fully understood.

Purpose of the Study:

  • To investigate CNTF levels and genotypes in the spinal cord of ALS patients.
  • To determine if CNTF expression differs between ALS patients and healthy controls.
  • To explore the relationship between CNTF levels, genotype, and motor neuron degeneration in ALS.

Main Methods:

  • Enzyme-linked immunoassay (ELISA) was used to quantify CNTF content in cervical spinal cord samples.
  • Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was employed for CNTF genotyping.

Related Experiment Videos

  • Samples were obtained from 9 ALS patients and 12 age-matched control subjects.

    • Main Results:

    • CNTF expression in the spinal cord showed a general trend of decrease in ALS patients compared to controls, irrespective of genotype.
    • This decrease in CNTF levels was statistically significant (p < 0.05) in homozygotes.
    • CNTF concentrations were markedly lower (p < 0.001) in the lateral corticospinal tract of homozygous ALS patients compared to controls.

    Conclusions:

    • Reduced CNTF expression in the spinal cord, especially within the lateral corticospinal tract, may be a characteristic feature of ALS.
    • The diminished CNTF levels could be associated with the progressive motor neuron loss observed in amyotrophic lateral sclerosis.
    • Further research is warranted to elucidate the precise mechanisms linking CNTF deficiency to ALS pathogenesis.